Antimicrobial Composition
By combining groups of metal nanoparticles with an average diameter of 5 nm to less than 20 nm with antimicrobial compounds to form poly(N-vinylpyrrolidone) coated antimicrobial compositions, the problem of antibiotic-resistant bacteria in the prior art is solved, and more efficient bactericidal and bacteriostatic effects are achieved.
Patent Information
- Application Number
- CN202580021251.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-14
- Filing Date
- 2025-03-14
- Publication Date
- 2026-11-10
AI Technical Summary
Existing antimicrobial compositions are ineffective against antibiotic-resistant bacteria and pose a risk of bacterial resistance, necessitating the development of more effective antimicrobial compositions.
A group of metal nanoparticles with an average diameter of 5 nm to less than 20 nm is coated with a poly(N-vinylpyrrolidone) polymer and combined with an antimicrobial compound to form a surfactant-free antimicrobial composition, wherein the concentration of the metal nanoparticles is less than 50% of its minimum bactericidal or bacteriostatic concentration.
It significantly improves the bactericidal and bacteriostatic effects of antimicrobial compositions, especially when used in synergy with antibiotic compounds, exhibiting higher bacteriostatic and bactericidal efficacy against Gram-positive and Gram-negative bacteria and reducing the risk of bacterial resistance.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to antimicrobial compositions and methods for preparing antimicrobial compositions. Background Technology
[0002] Metals including silver, copper, zinc, and mercury are known for their antimicrobial properties. Driven in part by the emergence of antibiotic-resistant bacteria, there has been renewed interest in the use of metallic silver as an antimicrobial agent, particularly in wound dressings. Metallic silver is a broad-spectrum antimicrobial agent that has been shown to be effective against such resistant bacteria, as well as other microorganisms. Current research indicates that metallic silver does not induce bacterial resistance due to its mode of action. The applicant's WO2015 / 040435 and WO2023 / 017240 describe methods for preparing cellulose fibers impregnated with metal nanoparticles, and methods for preparing solutions of metal nanoparticles. As used herein, the term "metal nanoparticles" refers to elemental metal particles with a median (i.e., average) diameter not exceeding 100 nm.
[0003] The growing resistance to antibiotics and antimicrobials has led to a demand for newer or more effective antibiotics and antimicrobials.
[0004] One object of the present invention is to provide novel or improved antimicrobial compositions. Summary of the Invention
[0005] The inventors have unexpectedly discovered that the presence of clusters of metal nanoparticles enhances existing antimicrobial and antibacterial compositions to a greater extent than would be expected from combining their individual effects.
[0006] This article discloses an improved antimicrobial composition comprising an antimicrobial compound and a group of metal nanoparticles.
[0007] According to a first aspect of the invention, an improved antimicrobial composition is provided, the antimicrobial composition comprising: an antimicrobial compound, and a group of metal nanoparticles including a polymer coating, wherein the average diameter of the metal nanoparticles is 5 nm to less than 20 nm, and the polymer coating comprises poly(N-vinylpyrrolidone).
[0008] The antimicrobial composition may further comprise a carrier. The carrier may comprise a fluid. The fluid may be water and / or an organic compound. The carrier may comprise a colloid (e.g., a gel) or an emulsion. The emulsion may comprise a water-in-oil or oil-in-water emulsion. The emulsion may comprise an emulsifier and / or a stabilizer. The antimicrobial composition may be present in a continuous or discontinuous phase. The carrier may comprise a cream. The carrier may comprise a gel, such as a hydrogel.
[0009] The antimicrobial composition may be surfactant-free.
[0010] The antimicrobial compound and / or the metal nanoparticle group may be present at concentrations below their respective minimum bactericidal concentrations (MBCs). For example, the antimicrobial compound and / or the metal nanoparticle group may be present at a concentration not exceeding 50% of their respective MBCs. In some embodiments, the antimicrobial compound and / or the metal nanoparticle group may be present at concentrations not exceeding 45%, 40%, 35%, 30%, 25%, or 20% of their respective MBCs. In some embodiments, the antimicrobial compound and / or the metal nanoparticle group may be present at concentrations of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, or 25% of their respective MBCs.
[0011] The antimicrobial compound and / or the metal nanoparticle group may be present at concentrations below their respective minimum inhibitory concentrations (MICs). For example, the antimicrobial compound and / or the metal nanoparticle group may be present at concentrations below 50% of their MICs. In some embodiments, the antimicrobial compound and / or the metal nanoparticle group may be present at concentrations not exceeding 45%, 40%, 35%, 30%, 25%, or 20% of their respective MICs. In some embodiments, the antimicrobial compound and / or the metal nanoparticle group may be present at concentrations of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, or 25% of their respective MICs.
[0012] The weight ratio of the antimicrobial compound to the metal nanoparticles in the antimicrobial composition can be from 1:4 to 4:1, such as 3:1, 2:1, 1:1, 1:2, or 1:3.
[0013] In some embodiments, the concentration of the metal nanoparticle cluster may be less than 20 ppm, or preferably less than 15 ppm. In some embodiments, the concentration of the metal nanoparticle cluster may be less than 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.75, 0.5, 0.25, or 0.1 ppm. In some embodiments, the concentration of the metal nanoparticle cluster is from 0.1 to 10 ppm, or from 0.5 to 5 ppm.
[0014] The metal nanoparticles may comprise a metal selected from the group consisting of silver, copper, zinc, selenium, gold, cobalt, nickel, zirconium, molybdenum, gallium, iron, or any combination thereof. In a series of preferred embodiments, the metal is silver and / or copper, and more preferably silver.
[0015] The metal nanoparticles may include a polymer coating. The polymer may be selected from the group consisting of polyamides, polyimides, polyethyleneimine, polyvinyl alcohol, pectin, albumin, gelatin, carrageenan, gums, cellulose or derivatives thereof, poly(N-vinylpyrrolidone), poly(N-vinylcaprolactam), and mixtures thereof. For example, the gum may be xanthan gum, guar gum, gum arabic, acacia gum, etc. For example, the cellulose derivative may be hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, etc. In a series of preferred embodiments, the polymer is poly(N-vinylpyrrolidone). Poly(N-vinylpyrrolidone) is also known as Povidone, Polyvidone, or PVP.
[0016] The weight-average molecular weight (M) of the polymer w The concentration of M in the polymer can be from 8 to 360 kg / mol, or from 20 to 80 kg / mol. w The value can be greater than 10, 15, 20, 25, 30, 32, 34, 36, 38, or 40 kg / mol. The M of the polymer... w It can be less than 360, 300, 250, 200, 150, 100, 80, 70, 60, 50, 45, 40, 38, 36, 34, 32, or 30 kg / mol. In a series of embodiments, the weight-average molecular weight (M) of the polymer is... w The values can be 25 to 45 kg / mol, 30 to 40 kg / mol, 32 to 38, or 34 to 36 kg / mol.
[0017] For example, in a series of embodiments, the polymer is poly(N-vinylpyrrolidone), and wherein the weight-average molecular weight (M) of the polymer is... wThe concentration is 30 to 40 kg / mol.
[0018] Multiple polymer-coated metal nanoparticles may comprise metal nanoparticles having a polymer coating with an average thickness of 40 to 100 nm. Optionally, the polymer-coated metal nanoparticles may have a polymer coating with an average thickness of 50 to 90 nm, 55 to 85 nm, 60 to 80 nm, or 65 to 75 nm.
[0019] The zeta potential of the metal nanoparticles can be less than 10 mV. Optionally, the zeta potential can be less than 9, less than 8, less than 7, or less than 6 mV. In some embodiments, the zeta potential can be between 4 and 6 mV, or it can be 5 mV.
[0020] The metal nanoparticle swarm may comprise metal nanoparticles with an average (median) diameter of 2 to 50 nm. In a series of preferred embodiments, the median diameter may be 5 to 20 nm, optionally 6 to 19 nm, 7 to 18, 8 to 17, 9 to 16 nm, or 10 to 15 nm. In some embodiments, the median diameter may be at least 5, 6, 7, 8, 9, 10, or 11 nm. In some embodiments, the median diameter may be less than 20, 19, 18, 17, 16, 15, 14, 13, or 12 nm.
[0021] The median diameter can be 5 to 15 nm, optionally 6 to 14, 7 to 13, 8 to 12, or 9 to 11 nm. In some embodiments, the median diameter can be at least 5, 6, 7, 8, 9, 10, or 11 nm. In some embodiments, the median diameter can be less than 20, 19, 18, 17, 16, 15, 14, 13, 12, or 11 nm.
[0022] The standard deviation of the diameter range of the nanoparticles within the group can be 4 to 15 nm, 5 to 14 nm, 6 to 13 nm, or 7 to 12 nm. In some embodiments, the standard deviation of the metal nanoparticle group can be greater than 4, 5, 6, or 7 nm. In some embodiments, the standard deviation of the metal nanoparticle group can be less than 15, 14, 13, 12, or 11 nm.
[0023] The D10 particle size of the metal nanoparticles can be less than 6 nm, less than 5 nm, or less than 4 nm. The D90 particle size of the metal nanoparticles can be greater than 15 nm. In some embodiments, the D90 particle size is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nm or greater than 30 nm. In some embodiments, the D90 particle size is between 15-25 nm, 16-24 nm, 17-23 nm, 18-22 nm, and 19-21 nm.
[0024] The metal nanoparticle group may include metal nanoparticles with diameters greater than 20 nm, 25 nm, 30 nm, 35 nm, or 40 nm.
[0025] The metal nanoparticle swarm may contain less than 15% nanoparticles with a diameter greater than 25 nm. Optionally, the swarm may contain less than 10%, 8%, 6%, or 5% nanoparticles with a diameter greater than 25 nm. In some embodiments, the swarm contains at least 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% nanoparticles with a diameter greater than 25 nm.
[0026] The metal nanoparticle clusters can be formed in the following ways:
[0027] a) Mixing the first alkaline aqueous solution with the polymer aqueous solution to form an alkaline polymer aqueous solution; and
[0028] b) Mix the alkaline polymer aqueous solution with a metal salt aqueous solution to form a solution of polymer-coated metal nanoparticles.
[0029] The first alkaline aqueous solution may contain hydroxides of Group I elements (e.g., sodium hydroxide or potassium hydroxide), carbonates of Group I elements (e.g., Na₂CO₃ or K₂CO₃), bicarbonates of Group I elements (e.g., NaHCO₃ or KHCO₃), tetraalkylammonium hydroxide (e.g., tetraethylammonium hydroxide), or mixtures thereof. In a series of preferred embodiments, the first aqueous solution contains sodium hydroxide and sodium carbonate.
[0030] The metal salt may comprise a metal selected from the group consisting of: silver, copper, zinc, selenium, gold, cobalt, nickel, zirconium, molybdenum, gallium, iron, or any combination thereof. In a series of preferred embodiments, the metal is silver.
[0031] The metal salt may be a nitrate, acetate, carbonate, bicarbonate, sulfate, or a mixture thereof. In a series of preferred embodiments, the metal salt is a nitrate. In a series of preferred embodiments, the metal salt is silver nitrate.
[0032] In a series of embodiments, solutions of polymer-coated metal nanoparticles can be obtained in the absence of any additional reducing agents and / or in the absence of surfactants.
[0033] In step (b), the mixing can be carried out at a temperature between 20°C and 120°C. For example, the temperature can be at least 20, 30, 40, 50, 60, 70, 80, 90, 100, or 110°C. The temperature can be below 110, 100, 90, 80, 70, 60, 50, 40, or 30°C. In a series of preferred embodiments, the temperature is 60 to 100°C.
[0034] The metal nanoparticles may be UV-stable. As used herein, the term "UV-stable" refers to the ability of metal nanoparticles to withstand prolonged exposure to ultraviolet (UV) radiation for a defined period of time without permanent damage. It should be understood that this definition may include UV radiation emitted by sunlight. Therefore, the UV stability of metal nanoparticles may be related to their expected shelf life. The metal nanoparticles may remain stable under UV light for more than one month. The metal nanoparticles may remain stable under UV light for at least 14 days. The metal nanoparticles may remain stable under UV light for at least 7 days. Therefore, the metal nanoparticles may be stable after exposure to sunlight for at least 7 days.
[0035] The antimicrobial compound may include antibiotics.
[0036] The antimicrobial compound may include one or more compounds selected from the group consisting of: beta-lactams, carbapenems, ansamycins, macrolides, quinolones, tetracyclines, glycopeptides, aminoglycosides, chloramphenicol, lipopeptide, bipyridine, ebselen, pseudomonoconic acid, polychlorophenoxyphenol, hypochlorite anion, antimicrobial peptides, and quaternary ammonium compounds.
[0037] The antimicrobial compound may include one or more of the following: cefotetan, rifampicin, azithromycin, nalidixic acid. The following antibiotics are listed: citric acid, tetracycline, ceftazidime, minocycline, doxycycline, ampicillin, amoxicillin, ebselen, spectinomycin, cefaclor, aztreonam, doripenem, ertapenem, imipenem, meropenem, kanamycin, gentamicin, chloramphenicol, streptomycin, nitrofurantoin, octenidine, mupirocin, triclosan, sodium hypochlorite, benzalkonium chloride, and chlorohexidine.
[0038] The antimicrobial composition may include one or more of the following: creams, ointments, ointments or drugs for topical or internal use.
[0039] According to a second aspect of the invention, a method for preparing an antimicrobial composition as described herein is provided. The method may include combining an antimicrobial compound with a group of metal nanoparticles. The group of metal nanoparticles may be in solution. The group of metal nanoparticles may be formed as described above with respect to the first aspect of the invention. The antimicrobial compound may be as described above.
[0040] According to a third aspect of the invention, a coating or treatment agent for a surface or substrate is provided, the coating or treatment agent comprising an antimicrobial composition as described herein.
[0041] According to a fourth aspect of the invention, a medical device is provided, the medical device comprising a coating or treatment agent as described herein.
[0042] The medical device may include absorbent articles. The absorbent articles may include at least one fiber impregnated with the antimicrobial composition. The fiber may comprise cellulose and / or its derivatives, and optionally may include at least one other type of fiber mixed therewith. In some embodiments, the at least one other type of fiber is: gelling fibers based on alginate, cellulose and modified cellulose, modified chitosan, guar gum, carrageenan, pectin, starch, polyacrylates or copolymers thereof, polyethylene oxide or polyacrylamide, or mixtures thereof; and / or non-gelling fibers based on polyester, polyethylene, polyamide, cellulose, thermoplastic bicomponent fibers, glass fibers, or mixtures thereof. In a range of embodiments, the at least one other type of fiber comprises carboxymethyl cellulose (CMC) and semi-synthetic fibers containing regenerated cellulose (commonly referred to as lyocell).
[0043] The medical devices and / or absorbent articles may include wound care dressings and / or bandages. The absorbent articles may be made of textiles or non-textiles.
[0044] In a range of embodiments, the medical device includes an absorbent article impregnated with the composition as described herein.
[0045] The medical device may include wearable items such as aprons, gloves, face shields, and / or personal protective equipment. Attached Figure Description
[0046] Embodiments of the present invention will now be described by way of example with reference to the accompanying drawings, in which:
[0047] Figure 1 This is a table showing the size distribution of the nanoparticle composition;
[0048] Figure 2 This is a table showing the results of the microdilution method determination of MIC and MBC.
[0049] Figure 3 This is a table of the MIC and MBC of a series of antimicrobial compounds targeting Escherichia coli (E. coli);
[0050] Figure 4 This is a table of the MIC and MBC of a series of antimicrobial compounds targeting Staphylococcus aureus;
[0051] Figure 5a and 5b This is a table of MIC and MBC for a series of antimicrobial compositions.
[0052] Examples and Experiments
[0053] Example 1 - Synthesis of Silver Nanoparticles
[0054] Prepare silver nanoparticle solutions as follows:
[0055] 1. Place 1459g of deionized (DI) water into the first container (e.g., a 3L beaker). Place the first container into a water bath set to the temperature in Table 1.
[0056] 2. Slowly add 625g of polyvinylpyrrolidone (PVP 40 - Sigma Aldrich) to a beaker while mixing to form a PVP solution. The molecular weight of PVP is as follows: M n =14,100 gmol -1 M w =35,300 gmol -1 And M w / M n =2.5.
[0057] 3. In the second container, dissolve 0.86 mol of sodium hydroxide and 0.20 mol of sodium carbonate in 1096 g of DI water to form a solution of sodium hydroxide and sodium carbonate. Place the second container in a water bath as well.
[0058] 4. In the third container, a silver nitrate solution is prepared by adding 0.93 mol of AgNO3 to 371 g of DI water. The third container is also placed in a water bath.
[0059] 5. Keep the first, second, and third containers in the water bath until they reach the water bath temperature.
[0060] 6. Once the first, second, and third containers reach 90°C, the sodium hydroxide and sodium carbonate solution in the second container is added to the PVP solution in the first container to form an intermediate solution.
[0061] 7. Next, the silver nitrate solution is slowly added to the intermediate solution while gently stirring. After all the silver nitrate solution has been added, the reaction is allowed to proceed for 20 minutes with continuous gentle stirring to obtain a silver nanoparticle solution.
[0062] 8. The silver nanoparticles in the solution have a coating comprising a polymer shell formed of PVP. The nanoparticle concentration was measured to be 7800 ppm.
[0063] Example 2 - Silver Nanoparticle Size Statistics
[0064] The silver nanoparticle solution in Example 1 was analyzed using Scanning Transmission Electron Microscopy (STEM) with ImageJ Fiji software to determine the dimensions of the silver core and PVP coating. The average diameter of the silver core was measured to be 18 nm, and the average PVP shell thickness was 73 nm.
[0065] Three other samples of the nanoparticle solution prepared according to Example 1 were analyzed in the same manner to determine the core size distribution of the silver nanoparticles. The results were... Figure 1 Listed in the table.
[0066] Samples A1 through A3 exhibit a range of nanoparticle core sizes, with average nanoparticle diameters of 11.85 nm, 14.6 nm, and 11.94 nm, respectively. The standard deviations are quite wide, at 8.2 nm, 10.76 nm, and 7.97 nm, respectively. The D10, D50, and D90 percentiles are shown in Table 1 below. In all three samples, less than 10% of the nanoparticles have a core diameter of less than 4 nm. Similarly, a large number of larger nanoparticles were observed, widely distributed between the median and D90 percentiles, and even particles up to 50 nm were observed.
[0067] Table 1
[0068]
[0069] Three commercially available nanoparticle solutions were obtained for comparative purposes. The following data were obtained from their respective Certificates of Analysis (CoA). Detailed size distribution data were not available, but the plots provided in the CoA show that for sample C1 there were no particles smaller than 4 nm or larger than 14 nm, or for sample C2 there were no particles smaller than approximately 17 nm or larger than approximately 40 nm.
[0070] Table 2
[0071]
[0072] Example 3 - Determining the MIC of nanoparticle solutions
[0073] Using broth microdilution assays in accordance with EUCAST best practice guidelines, the minimum inhibitory concentrations (MICs) of the nanoparticles prepared according to Example 1 (sample A) and compared to samples B through D were investigated. MICs against Escherichia coli 8739 and Staphylococcus aureus 6538 were determined.
[0074] The results of the experiment are Figure 2The table shows that the MICs listed in the upper table are percentages of the initial sample concentration, and the MICs listed in the lower table are in ppm (equivalent to pg / ml). Sample A was found to have an MIC of 3.096 ppm against E. coli and 6.191 ppm against Staphylococcus aureus, demonstrating extremely high efficacy against both Gram-negative and Gram-positive bacteria.
[0075] Surprisingly, nanoparticle solution sample A was found to be significantly more effective than any of the three commercially available solutions B through D. For *E. coli*, the MICs for samples B through D were 312.5 ppm, 78.125 ppm, and 18.750 ppm, respectively, indicating an approximately six-fold improvement over the best-performing comparative sample D. Compared to sample B, sample A was two orders of magnitude more effective at inhibiting the growth of *E. coli*.
[0076] The concentration required for sample A to inhibit *E. coli* was found to be half that required to inhibit *S. aureus*. This finding was reproduced for samples C and D. It is possible that sample B might be slightly more effective against *E. coli* than *S. aureus*, but this was not observed in this experiment and was not investigated further. To avoid being bound by theory, it is speculated that the cellular structural differences between Gram-positive and Gram-negative bacteria may explain the enhanced efficacy against Gram-negative *E. coli*.
[0077] Furthermore, not wanting to be bound by theory, it is speculated that the greater efficacy of sample A compared to samples B through D may be due to a wider particle size distribution in solution. Samples B and C contain nanoparticles with average diameters smaller and larger than those of sample A, respectively. However, the standard deviations of 1.5 nm and 4 nm are less than one-quarter and one-half of the standard deviations observed in samples A1 through A3 of Example 2, respectively. It is speculated that nanoparticles of different sizes have different target sites on bacterial cells.
[0078] Example 4 - Charge
[0079] The charge of the metal nanoparticles formed by the process described in Example 1 was measured and recorded in Table 3 below. Measurements were performed using an Anton-Paar Litesizer 500. The sample was diluted at a ratio of 1 drop to 1 ml of MilliCi® water, and gently shaken by hand to homogenize the dispersion before transferring it to an omega zeta potential cuvette. Tests were conducted at 25°C with a temperature stabilization time of 5 seconds. The Smoluchowski approximation was used as an approximation with a Henry factor of 1.5. The power supply was set to automatic with a maximum voltage of 200 V. Data quality was set to manual, with 100 measurements performed. Each sample was tested three times, and the average values are recorded in Table 3.
[0080] The values for sample C were obtained from the product's analytical certificate, and the range for sample D was obtained from the supplier's marketing materials. It has been found that the nanoparticles prepared by the process of Example 1 have a significantly lower charge than the commercially available product sample C.
[0081] Table 3
[0082]
[0083] To avoid being bound by theory, it is assumed that this charge reduction is due to the relatively mild conditions under which nanoparticles are formed in solution. In Example 1, a solution of relatively low concentrations of NaOH and NaCO3 was added to the PVP solution, thus having a limited effect on the polymer's charge. Conventional processes are known to use higher concentrations of alkali or to reduce the silver salt with citric acid. This was confirmed by FTIR spectroscopy, which showed that the charge on the PVP did not change significantly during the preparation of the silver nanoparticles.
[0084] Furthermore, not wanting to be bound by theory, it is speculated that the lower charge of the nanoparticles of this invention in solution may be the reason for their greater efficacy compared to comparative products. It is believed that any repulsive effect caused by the particle's charge is minimized, thus leading to better contact with bacterial cells. It should be understood that bacterial cell walls are negatively charged, so strongly negatively charged nanoparticles may be repelled, thereby reducing their effectiveness. It is also speculated that the combination of near-neutral charges is directly related to a wider particle size distribution due to increased aggregation during formation, and both factors are associated with improved efficacy.
[0085] Example 5 - Synergistic Antimicrobial Effect
[0086] Further experiments were conducted to determine the effectiveness of the nanoparticles, combined with a range of antimicrobial compounds, against *Escherichia coli* 8739 and *Staphylococcus aureus* 6538. Microdilution assays in broth, performed according to EUCAST best practice guidelines, were performed to determine... Figure 3 and 4 The table lists the MIC and minimum bactericidal concentration (MBC) for each antimicrobial compound.
[0087] The tests were then repeated by adding silver nanoparticles (sample A) prepared according to Example 1 to each well. Silver nanoparticles were added to each well to provide a concentration of 25% of the MIC (as determined in Example 3). For the *E. coli* test, the concentration of silver nanoparticles in the well was 0.77 ppm, and for the *S. aureus* test, the concentration was 1.55 ppm. A concentration of silver nanoparticle solution representing the lowest effective concentration was selected, thus it was expected that adding only silver nanoparticles would have no effect on the MBC or MIC of the antimicrobial compound. The results for the *E. coli* test are recorded in... Figure 3 In the middle, and the test results for Staphylococcus aureus (S. aureus) were recorded in Figure 4 middle.
[0088] Figure 3 The results showed that for 18 antimicrobial compounds tested against E. coli, a synergistic effect was observed with the addition of silver nanoparticles (sample A) at a concentration of 0.77 ppm (25% of the MIC), resulting in a reduction of both the MIC and MBC by at least half. For the remaining 11 antimicrobial compounds, neither the MIC nor the MBC changed or showed a slight improvement.
[0089] The combination of silver nanoparticles and antimicrobial compounds was found to be particularly effective against aminoglycosides. The addition of 0.77 ppm silver nanoparticle solution (sample A) reduced the MIC and MBC of spectinomycin against E. coli to 1 / 64, kanamycin to 1 / 66 to 1 / 128, streptomycin to 1 / 32, and gentamicin to 1 / 1300.
[0090] In addition to the compounds mentioned above, the addition of silver nanoparticles (Sample A) was particularly effective for ebuselenium. The addition of a 0.77 ppm silver nanoparticle solution (Sample A) resulted in a reduction of approximately five orders of magnitude in the MIC and MBC against *E. coli*. This data is limited by the assays performed, and even greater improvements could be demonstrated if reliable assays and measurements could be performed at such low concentrations.
[0091] like Figure 4 As shown, similar effects were observed in tests of 17 antimicrobial compounds against Staphylococcus aureus. Each antimicrobial compound was tested in combination with 1.55 ppm of silver nanoparticles prepared according to Example 1.
[0092] Once again, the combination of silver nanoparticles and aminoglycosides showed consistent improvement, although the magnitude was lower compared to the case with E. coli. Ebuselenium again showed the best results, with MBC reduced to 1 / 2000 and MIC reduced to 1 / 500, a result primarily limited by the larger initial efficacy of ebuselenium against Gram-positive Staphylococcus aureus.
[0093] The observed synergistic effect between antimicrobial compounds and silver nanoparticles was inconsistent between Gram-positive and Gram-negative bacteria. Without being bound by theory, it is speculated that this variation in efficacy reflects the attack patterns of each antimicrobial compound.
[0094] Example 6 - Comparison with Commercial Nanoparticles
[0095] The synergistic effect of the antimicrobial compounds and silver nanoparticles was further investigated by comparison with commercially available silver nanoparticle solutions. A subset of the antimicrobial compounds tested in Example 5 was selected, and microdilution assays were repeated using sample C (NanoComposix, 25 nm silver nanoparticles, PVP, Econix™). The procedure of Example 5 was repeated by adding sample C to each well to provide a concentration of sample C representing 25% of the MIC.
[0096] Figure 5aThe comparison results of the MIC and MBC of eight antimicrobial compounds against Escherichia coli are shown. The table shows the MIC and MBC of the antimicrobial compounds alone, the MIC and MBC of the antimicrobial compounds in combination with 0.77 ppm of sample A (prepared according to Example 1), and finally the MIC and MBC of the antimicrobial compounds in combination with 19.5 ppm of sample C. The concentrations of samples A and C used were 25% of their respective MICs when used alone, and represent concentrations at which no inhibitory effect was expected.
[0097] Figure 5b The same data are shown for Staphylococcus aureus (S. aureus). Sufficient sample C was added to the cells to produce a concentration of 39 ppm, which is 25% of the MIC determined in the examples.
[0098] For both *E. coli* and *S. aureus*, the addition of nanoparticle solution sample C resulted in a decrease in the MIC and MBC of all tested antimicrobial compounds. Neither sample A nor sample C improved the efficacy of nalidixic acid against *S. aureus*, although both effectively reduced the MIC and MBC against *E. coli*. The combination of sample C and ebuselenium was found to be more effective against *E. coli* than sample A, although the final values were not determined due to reaching the limits of the assay plate. This improvement was not reproducible for *S. aureus*, where sample A resulted in a greater reduction in the MIC and MBC of ebuselenium.
[0099] The nanoparticle solution sample C exhibited a similar synergistic effect with the tested antimicrobial compounds, but at a lower level compared to sample A. These results were achieved using significantly higher concentrations of sample C in the test wells; 19.5 ppm and 39 ppm, compared to 0.77 ppm and 1.55 ppm used for sample A, respectively. Without being bound by theory, it is assumed that the improved results of sample C against selenium iberis and E. coli are due to the increased concentration rather than to the composition of sample C.
Claims
1. An antimicrobial composition comprising: Antimicrobial compounds; and A group of metal nanoparticles comprising a polymer coating, wherein the average diameter of the metal nanoparticles is 5 nm to less than 20 nm, and the polymer coating comprises poly(N-vinylpyrrolidone).
2. The antimicrobial composition according to claim 1, wherein the antimicrobial compound is an antibiotic.
3. The antimicrobial composition according to claim 1 or 2, wherein the antimicrobial composition further comprises a carrier, and optionally wherein the carrier comprises a fluid.
4. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial compound and / or the metal nanoparticle group are present at a concentration below their respective minimum bactericidal concentration (MBC); preferably wherein the concentration of the antimicrobial compound and / or the metal nanoparticle group is less than or equal to 50% of their MBC.
5. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial compound and / or the metal nanoparticle group are present at a concentration below their respective minimum inhibitory concentration (MIC); preferably wherein the concentration of the antimicrobial compound and / or the metal nanoparticle group is less than 50% of their MIC.
6. The antimicrobial composition according to any one of the preceding claims, wherein the concentration of the metal nanoparticle cluster is less than 15 ppm.
7. The antimicrobial composition according to any one of the preceding claims, wherein the metal nanoparticles comprise silver and / or copper.
8. The antimicrobial composition according to any one of the preceding claims, wherein the polymer has a weight-average molecular weight (Mi). w The concentration ranges from 20 to 80 kg / mol.
9. The antimicrobial composition according to any one of the preceding claims, wherein the zeta potential of the metal nanoparticle cluster is less than 10 mV, preferably less than 5 mV.
10. The antimicrobial composition according to any one of the preceding claims, wherein the average diameter of the metal nanoparticle cluster is 10 to 15 nm, and / or the standard deviation of the metal nanoparticle cluster is 4 to 15 nm.
11. The antimicrobial composition according to any one of the preceding claims, wherein the D10 particle size of the metal nanoparticles is less than 4 nm, and / or wherein the D90 particle size of the metal nanoparticles is more than 15 nm.
12. The antimicrobial composition according to any one of the preceding claims, wherein the metal nanoparticles are UV stable; optionally, wherein the UV stability of the metal nanoparticles is maintained for at least one week, at least two weeks, or at least one month.
13. The antimicrobial composition according to any one of the preceding claims, wherein the silver nanoparticle clusters are formed in the following manner: a) Mixing the first alkaline aqueous solution with the polymer aqueous solution to form an alkaline polymer aqueous solution; and b) Mix the alkaline polymer aqueous solution with a metal salt aqueous solution to form a solution of polymer-coated metal nanoparticles.
14. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial compound comprises one or more compounds from the group consisting of: β-lactams, carbapenems, anesamycins, macrolides, quinolones, tetracyclines, glycopeptides, aminoglycosides, chloramphenicol, lipopeptides, bipyridine, ibuselenium, pseudomonadic acid, polychlorophenoxyphenol, hypochlorite anion, antimicrobial peptides, and quaternary ammonium compounds.
15. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial compound comprises one or more of the following: cefotetan, rifampin, azithromycin, nalidixic acid, tetracycline, ceftazidime, minocycline, doxycycline, ampicillin, amoxicillin, ibuprofen, spectinomycin, cefaclor, aztreonam, daripenem, ertapenem, imipenem, meropenem, kanamycin, gentamicin, chloramphenicol, streptomycin, nitrofurantoin, ostinidine, mupirocin, triclosan, sodium hypochlorite, benzalkonium chloride, and chlorhexidine.
16. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial composition has greater antimicrobial efficacy against Gram-negative and / or Gram-positive bacteria compared to the metal nanoparticle group.
17. The antimicrobial composition according to any one of the preceding claims, wherein the antimicrobial compound and the group of metal nanoparticles comprising a polymer coating have a synergistic effect of reducing the MIC and / or MBC of the antimicrobial compound.
18. The antimicrobial composition according to any one of the preceding claims, wherein the composition comprises one or more of the following: a cream, ointment, balm, or medicament for topical or internal use.
19. A method for preparing an antimicrobial composition according to any one of the preceding claims, the method comprising combining an antimicrobial compound with a swarm of silver nanoparticles.
20. A coating or treatment agent for a surface or substrate, said coating or treatment agent comprising an antimicrobial composition according to any one of claims 1 to 17.
21. A medical device comprising the coating or treatment agent according to claim 20.
22. The medical device of claim 21, wherein the medical device is a wound care dressing or bandage.
23. The medical device of claim 21 or claim 22, wherein the medical device comprises an absorbent article, optionally wherein the absorbent article comprises at least one fiber impregnated with the antimicrobial composition.
24. The medical device of claim 23, wherein the at least one fiber comprises cellulose or a derivative thereof, and the device optionally further comprises at least one other type of fiber mixed therewith.
Citation Information
Patent Citations
Cellulose fibres
WO2015040435A1
Cellulose fibres
WO2023017240A1
